Analyst Targets Rise for Zebra, Amgen; AMD Gets Trimmed

Analysts lifted price targets across several names on Wednesday, with industrial technology and biotech leading the upgrades while semiconductors faced mild headwinds.

ZBRA saw the most decisive move. The consensus target for Zebra Technologies rose to $417.25 from $414.85, extending a run of upward revisions for the warehouse automation specialist. Short interest sits at just 3% of free float, suggesting little bearish pushback against the bullish analyst stance.

AMGN received a $7 target price bump, with the consensus now at $404.32 versus $397.32 previously. The move reflects confidence in Amgen's pipeline. The biotech giant carries a $252 billion market cap and minimal short interest.

The day's most notable downward revision hit AMD. The consensus target dipped to $648.24 from $649.38. The move is small in absolute terms but stands out given AMD's $762 billion market cap and 42 analyst votes on record. Any softening in that large a crowd carries weight.

BKNG also saw its consensus target trimmed, to $231.31 from $232.46. Booking Holdings draws coverage from 38 analysts, making even a modest dip in the aggregate target significant for sentiment.

EW at Edwards Lifesciences logged multiple rating changes simultaneously, with the sell count dropping from 22 to 24 votes and hold coverage shifting slightly. The average target nudged to $102.53.

AIG and PRU both picked up target increases in the insurance space, suggesting sector-wide optimism heading into year-end reserve reviews.